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Abstract
Purpose. – GADIS aims at determining the prevalence of generalized anxiety disorder (GAD) and major depression (MD) in primary care
and their impact on the patient’s functioning in Belgium and Luxemburg.
Method. – A large scale screening program was conducted at the consultation of general practitioners to detect patients with GAD and MD
according to DSM-IV criteria. We collected additional data regarding the use of hypnotic, tranquilizer, antidepressant and analgesic medica-
tions. Impact on the patient was assessed with the Sheehan disability scale.
Results. – Three hundred GP’s in Belgium and Luxemburg were asked to screen 50 consecutive patients. Of the 13,677 analyzed patients,
8.3% were diagnosed to have GAD and 6.3% MD. Comorbidity was observed in 4.2% of patients. The prevalence was much higher in the
French-speaking part of Belgium. GAD and MD were associated with impairment in social, familial and professional functioning. Only a
minority of patients with GAD and/or MD was treated with an antidepressant and almost half of subjects with GAD and/or MD were treated
with a tranquilizer.
Conclusion. – Prevalence rates of GAD and MD in primary care in Belgium are comparable to other countries. GAD and MD are disabling
conditions. Antidepressants are still used only in a minority of subjects with GAD and/or MD in primary care in Belgium and Luxemburg. The
prevalence of GAD and MD appears to be much higher in French-speaking parts of Belgium.
© 2005 Elsevier SAS. All rights reserved.
Keywords: Depression; Anxiety; Prevalence; Primary care; Impairment; Generalized anxiety disorder; Major depression
1. Introduction
A number of epidemiological studies have shown that
depression and anxiety disorders are highly prevalent in the
general population and in primary care [10,22]. These diag-
noses are, however, frequently missed due to patient related
reasons such as the stigmatization of mental illness and phy-
sician related reasons such as insufficient awareness of the
diagnoses, and cause these illnesses to remain untreated. Gen-
eralized anxiety disorder (GAD) is characterized by chronic
worry, anxiety and tension and frequently occurs concomi-
tantly with other disorders, mainly depression [10]. GAD and
major depression (MD) are debilitating illnesses, even more
than other chronic illnesses such as diabetes or arthritis [20]
with an important impact on the personal life of the patients
and their family.
With the availability of new treatment options, there is a
growing interest to detect and treat these illnesses at the pri-
mary care level.
GADIS was aimed at detecting GAD and depression in
the primary care setting in Belgium and Luxemburg and also
at measuring the impact of these conditions on the patient’s
functioning. In addition, the study aimed at describing the
pharmacological treatment received by the patients.
2. Subjects and methods
Three hundred general practitioners were asked to partici-
pate in a large scale screening program. In order to have rep-
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resentative samples of patients consulting primary care in Bel-
gium and Luxemburg, the investigators had to be primary care
physicians, geographically distributed over Belgium and Lux-
emburg, with medium to large size practices. Every medical
representative of the Wyeth laboratory selected five GP’s in
his/her sector complying with these criteria.
The validated French and Dutch translations of GAD and
major depressive episode (MD) sections from the Mini Neu-
ropsychiatric Interview (MINI) were used with permission
of the authors to make the diagnoses of GAD and MD accord-
ing to DSM-IV criteria [16]. Physicians were not trained in
the use of the MINI.
In order to avoid bias in the selection of the patients, the
participating GP determined the dates of the consultations at
their office at which all consecutive patients were going to be
screened. Between November 2001 and March 2002, each
physician screened 50 consecutive patients of at least 18 years
who presented at their consultation at the previously fixed
time periods.
The patient was interviewed by the GP with the GAD and
MD sections of the MINI [16]. The Case Report Form, filled
by the GP, captured the reason for consultation, the current
hypnotic, tranquilizer, antidepressant or analgesic medica-
tions.
In order to make the study feasible for the majority of GP’s,
250 GP’s were asked to collect the information on treatment
and disability only in patients that screened positive for GAD
or MD, whereas 50 GP’s were asked to collect all informa-
tion in all their screened subjects. The latter group of GP’s
thus generated the information for the control group of sub-
jects without GAD and MD, on use of medication and
patient’s functioning. Most characteristics were found to be
similar between both groups of patients (age, region, reason
for consultation). Both groups differed significantly (P
= 0.043) for gender with a slightly higher proportion of
women in the latter group (57.2%) compared with the former
group (55.0%).
Impact on the patient’s functioning was assessed using the
Sheehan disability self-assessment scale [15].
Finally, the protocol was approved by the Ethics Commit-
tee of the Catholic University of Leuven and patients were
required to provide written informed consent prior to the
screening.
3. Statistics
In tables, results are expressed as mean ± standard devia-
tions (S.D.) for quantitative variables and as counts and pro-
portions (prevalence) for categorical findings. Prevalence rates
were associated with their 95% confidence intervals when-
ever needed. Mean values were compared by classical one-
way analysis of variance (ANOVA) and proportions by the
v2-square test for contingency tables. Non parametric
Kruskal–Wallis and Wilcoxon tests were also used for com-
paring samples from different groups. Correlation coeffi-
cients (classical or non parametric Spearman) were calcu-
lated to measure the association between continuous variables.
General linear models were used to measure the effect of sev-
eral “independent” factors on a “dependent” variable. Logis-
tic regression analysis was used to assess the relationship
between a binary outcome variable (e.g. GAD or MD) and a
set of independent variables. The approach was also utilized
to derive relative risk (RR) or odds ratio (OR) quantities. All
results were considered to be statistically significant at the
5% level (P < 0.05) (two-tailed). Statistical analyses were
always carried out on the maximum number of data available
(pair-wise deletion of missing data which explains slight dif-
ferences of N in some tables) using the SAS (version 8.2 for
Windows) and S-Plus (version 6.0) software packages.
4. Results
4.1. Study population
Fifteen thousand (15,000) patients were expected to be
screened. However, not all GP’s included 50 patients and a
number of files were excluded because of the large number
of missing data. Ultimately, a sample of 13,677 patients con-
sulting their general practitioner in Belgium and Luxemburg
were included in the analyses.
4.2. Characteristics of the patient population
Detailed characteristics of patients are shown in Table 1.
A significant age difference was observed between men
and women (50.4 ± 17.0 vs. 48.8 ± 17.4 years, respectively;
P < 0.0001). Regions were homogeneous with respect to gen-
der (data not shown) but not to age (P < 0.0001). Patients
were older in Brussels (52.3 ± 17.8 years) than in Wallonia
(49.6 ± 17.1 years), Flanders (49.1 ± 17.2 years) and Luxem-
burg (45.8 ± 16.7 years).
Reasons for consulting the GP were not the same in the
regions (P < 0.0001). The proportion consulting for anxiety
or depression was significantly lower in Flanders (3.4%) and
Table 1
Characteristics of the patient population (n = 13677)
Variable Mean ± S.D.
(or number and proportions)










Chronic disease 5636 (44.4%)
New illness 6467 (50.9%)
Anxiety or depression 600 (4.7%)
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Luxemburg (2.2%) than in Wallonia (6.6%) and Brussels
(5.7%). Reasons for consulting were also significantly related
to gender (P < 0.0001) and age (P < 0.0001) with a signifi-
cantly higher proportion of women consulting for anxiety and
depression (67%) than for chronic disease (54%) or new ill-
ness (56%). As expected, patients consulting for a chronic
disease were found to be older (59.1 ± 15.0 years) than those
consulting for anxiety or depression (44.3 ± 12.8 years), them-
selves being older than those presenting with a new illness
(41.7 ± 15.2 years).
4.3. Overall prevalence of GAD and/or MD
Table 2 gives the prevalence of GAD and MD in the entire
patient population.
The prevalence of GAD alone (4.1%) was about twice as
high as MD alone (2.1%). The prevalence of the combination
of the two disorders reached 4.2%. Overall, 10.4% of the
patients were diagnosed as GAD and/or MD.
4.4. Prevalence according to gender
As seen in Table 3, there was a significant effect of gender
on the prevalence of GAD alone (P < 0.0001) and to a lesser
extent on MD alone (P = 0.029). In each case, prevalence in
women was significantly higher than in men. The RR varied
between 1.3 and 2.0.
4.5. Prevalence according to age
Fig. 1 clearly demonstrates a quadratic evolution
(P < 0.0001) of the prevalence of GAD, which increased until
the age of 50 years and thereafter dropped to lower values.
The prevalence of MD follows the same trend pattern but less
strikingly (P < 0.0017).
4.6. Prevalence according to regions
Highly significant differences in GAD/MD prevalence
rates were observed between regions (P < 0.0001) (Table 4).
Prevalence rates were significantly higher in Wallonia,
Brussels and even in Luxemburg than in Flanders, confirm-
ing the differences observed above in the reasons for consult-
ing. Overall prevalence rates reached 13.1% in Wallonia,
13.6% in Brussels and 11% in Luxemburg, but only 7.9% in
Flanders.
4.7. Prevalence in patients consulting for
anxiety/depression
The prevalences of GAD and MDD in the 600 patients
(4.7% of the total sample) who reported anxiety/depression
as reason for consulting their GP is displayed in Table 5. A
total of 84.6% of those patients were positive for at least one
of the two disorders. No difference existed regarding preva-
lence rates according to gender in this subsample.
4.8. Existing treatment
Among patients with a positive diagnosis (GAD alone, MD
alone or GAD + MD), 48% were being treated with tranquil-
izers at the time of the visit to the general practitioner. The
proportions were 32% for antidepressants, 27% for hypnot-
ics, and 24% for analgesics, respectively. Differences were
Table 2
Prevalence of MD and GAD (n = 13480)
Disorder Number Prevalence 95% CI
GAD alone 555 4.1% 3.78–4.45
MD alone 288 2.1% 1.89–2.38
GAD + MD 565 4.2% 3.85–4.53
All GAD 1120 8.3% 7.84–8.77
All MD 853 6.3% 5.92–6.74
Total 1408 10.4% 9.93–11.0
Table 3






GAD alone 385 (5.20%) 167 (2.80%) <0.0001 1.86
MD alone 176 (2.38%) 109 (1.83%) 0.029 1.30
GAD + MD 400 (5.40%) 159 (2.67%) <0.0001 2.03
Total 961 (13.0%) 435 (7.29%) <0.0001 1.78
Table 4
Prevalence rates of GAD and MD according to regions
Disorder Flanders, n = 6842 Wallonia, n = 4544 Brussels, n = 1498 Luxemburg, n = 539 P-value
GAD alone 216 (3.2%) 229 (5.0%) 71 (4.7%) 29 (5.4%) <0.0001
MD alone 116 (1.7%) 107 (2.3%) 55 (3.7%) 10 (1.9%) <0.0001
GAD + MD 206 (3.0%) 258 (5.7%) 78 (5.2%) 20 (3.7%) <0.0001
Total 538 (7.9%) 594 (13.1%) 204 (13.6%) 59 (11.0%) <0.0001
Fig. 1. Distribution of GAD and MD according to age.
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found between diagnostic categories for hypnotics, tranquil-
izers and antidepressants but not for analgesics (Table 6). For
all types of medication, drug use was higher in patients suf-
fering from comorbid GAD/MD.
The average number of drugs taken per day varied between
2.3 and 2.7 (average 2.5 ± 2.1) and a significant difference
was observed between GAD alone and GAD + MD
(P = 0.0065), with a higher number of drugs for the latter.
When comparing “positive” patients (for GAD/MD) with
patients from the control group (see Section 2), we found
significantly higher proportions of drug use in the former
group, even after adjusting for cofactors like gender, age and
region (P < 0.0001) (Table 7). Moreover, the number of types
of drugs taken was also higher in the former group
(P < 0.0001).
4.9. Impact on patient
On the Sheehan disability scale, the patient rates the degree
of impairment from 0 to 10 in three domains of his/her life:
work, social life and family life. Higher scores indicate higher
levels of impairment. Results on the Sheehan disability scale
are given in Table 8, not only for each diagnostic category
but also for patients with or without GAD and/or MD.
Patients with GAD and/or MD had very significantly higher
item scores than control patients (P < 0.0001). Also, patients
combining the two disorders had higher scores than those
affected by a single disorder.
Correlations between all items of the Sheehan disability
scale were highly significant (data not shown).
The P-values between the three diagnostic groups were all
<0.0001 and the P-values between positive and negative
patients were all <0.0001.
In order to exclude a possible effect of gender and age
upon the association of diagnosis and disability, a multiple
regression analysis was conducted with disability as depen-
dent variable and diagnosis, gender and age as independent
variables. No effect of age was observed. A statistically sig-
nificant independent effect was found for diagnosis, gender
for the three Sheehan subscales (respectively work: diagno-
sis, P < 0.0001; gender, P = 0.0014; social: diagnosis,
P < 0.0001; gender, P = 0.0016; familial: diagnosis,
P < 0.0001; gender, P = 0.0046). The interaction between
Table 5
Prevalence of GAD and MD in patients consulting for anxiety/depression (n
= 600)
Disorder Number Prevalence (%) 95% CI
GAD alone 135 22.7 17.0–28.4
MD alone 89 15.0 10.1–19.9
GAD + MD 279 46.9 40.2–53.4
All GAD 417 69.6 58.2–81
All MD 369 61.9 54.6–69.2
Total 503 84.6 77.0–92.2
Table 6









Hypnotics 125 (23%) 75 (27%) 163 (31%) 0.025 363 (27%)
Tranquilizers 236 (44%) 115 (40%) 306 (55%) <0.0001 657 (48%)
Antidepressants 130 (24%) 83 (29%) 132 (42%) <0.0001 445 (32%)
Analgesics 116 (23%) 58 (22%) 138 (27%) 0.13 312 (24%)
Number drugs per day 2.3 ± 2.0 a 2.6 ± 2.2 2.7 ± 2.1a 0.0065 2.5 ± 2.1
a Scheffé test.
Table 7





OR 95% CI Adjusted OR
Hypnotics 363 (27%) 204 (11%) 3.12 2.58–3.77 3.87
Tranquilizers 657 (48%) 273 (14%) 5.51 4.67–6.50 6.71
Antidepressants 445 (32%) 120 (6.2%) 7.15 5.76–8.88 7.09
Analgesics 312 (24%) 321 (17%) 1.59 1.33–1.89 1.69
Number drugs per day 2.5 ± 2.1* 1.9 ± 2.0 – – –
* P < 0.0001.
Table 8












Work 5.8 ± 2.3 6.3 ± 2.2 7.1 ± 1.9 6.4 ± 2.2 1.7 ± 2.1
Social 5.8 ± 2.3 6.3 ± 2.3 7.3 ± 1.9 6.5 ± 2.2 1.4 ± 2.0
Family 5.8 ± 2.4 6.2 ± 2.3 7.3 ± 2.0 6.5 ± 2.3 1.4 ± 2.0
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gender and diagnosis was found to be statistically significant
for the subscale work functioning (P = 0.04), marginally sig-
nificant for social functioning (P = 0.06) and not significant
for familial functioning. This means that independently of a
gender effect on disability, diagnosis of MD and/or GAD has
a separate contribution to disability. Furthermore, women with
GAD and/or MD were found to be more professionally dis-
abled than men with GAD and/or MD.
The levels of impairment were clearly different in patients
with or without GAD and/or MD. The distribution of patients
according to the score on the Sheehan disability scale showed
that most patients who were positive for GAD and/or MD
had scores of 5 or higher. Patients who did not receive a diag-
nosis of GAD or MD rarely had scores higher than 4.
Of the positive patients 83% have a score of 5 or more on
the work item compared to 12% of the control patients. For
the social function, 83% of positive patients and 10% of con-
trol patients have a score of at least 5 and regarding family
function 80% of positive patients have a score of at least
5 compared to 10% of control patients.
5. Discussion
5.1. Prevalence
The prevalence of GAD obtained in the current study
(8.3%) compares well with the literature where the preva-
lence of GAD in primary care ranges from 6.4% to 14.9%
but approximates 8% in several studies [8,14,19,21]. It is
somewhat higher than in the general population, confirming
that patients suffering from GAD and MD more frequently
consult the primary care physician. A recent Belgian study
using a different screening instrument (Prime-MD) in
2316 patients showed a higher prevalence for generalized
anxiety (10.3%) and a much higher prevalence of MD (13.9%
as compared with 6.3% in the present study) [1]. These dif-
ferences in a similar population can be due to the inclusion of
patients seen during home visits (29.6% of the sample) in
this previous study. These patients who are unable or unwill-
ing to attend the GP office could be characterized by more
psychiatric disturbances.
The point prevalence obtained in GADIS only detected
the patients who have currently all the diagnostic criteria for
GAD and MD. They do not include the patients with a prior
diagnosis who no longer fulfill all the criteria because they
receive adequate treatment (partial or complete remission)
neither subjects with a subsyndromal condition.
In the screened population, 4.7% of the patients came to
see their GP because of anxiety or depression whereas in
10.4% a new diagnosis was made. This possibly means that
many patients with GAD and/or MD are not recognized by
their GP’s. Another possibility (which does not exclude the
former) is that GAD and or MD is prevalent in patients with
organic conditions and that therefore these patients are not
classified by their GP as consulting for anxiety and/or depres-
sion. A third possibility is the fact that many anxious and
depressive patients present with somatoform complaints [5].
In this subgroup, a diagnosis of GAD or MD was made in
84.6% of patients, with slightly higher rate of GAD as com-
pared to MD (69.6% vs. 61.9%) and both diagnoses present
in about half of the subjects. Surprisingly, 15.4% of those
patients did not received any diagnosis. They probably did
not fulfill all criteria for a DSM-IV diagnosis despite their
specific complaints.
GADIS confirms that more women than men suffer from
generalized anxiety and from depression. The higher preva-
lence in women is particularly pronounced for GAD and GAD
+ depression. Also significant, the difference between men
and women for depression without GAD is much less marked.
This finding coincides with the conclusion of the review of
Simonds and Whiffen [17]. However, a consultation bias can
not be excluded in our study.
The prevalence varies according to age. For GAD the
prevalence raises between the age of 20 and 50 and declines
after 60. MD prevalence also increases with age but less strik-
ingly. In previous studies in primary care the highest fre-
quency of GAD was found between 35 and 60 years [21].
The GADIS data are in agreement with these results. The
reason why the prevalence is lower in older patients can be
due to inclusion of patients coming to the consultation of the
general practitioner. Many older patients are visited at home
by their doctor. Sometimes this is due to problems of mobil-
ity but this could also result from anxiety and depression. If
GADIS would have included patients seen at their homes the
prevalence may have been somewhat higher. Most data, how-
ever, indicate a decrease in prevalence after 60 years of age.
The lower prevalence of GAD and MD in the elderly may be
explained by the fact that older persons often live in nursing
homes. They do not usually go to the physician’s office but
instead call upon the GP whenever needed.
GADIS shows quite impressive regional differences in
prevalence. More patients in Wallonia and Brussels have a
positive diagnosis for GAD and/or MD than patients in
Flanders. The use of psychotropic medication is also higher
in the French-speaking parts of Belgium. These results con-
firm previous data demonstrating extremely high prevalence
of anxiety and affective disorders in two French-speaking Bel-
gian provinces [13]. GADIS did not capture information that
may explain these regional differences. Possible reasons
include differences in socio-economic factors between the
regions. The economic conditions between Belgian regions
are very different, for example the percentage of unemploy-
ment is 16.7% in Wallonia, 20.3% in Brussels and 7.5% in
Flanders (Belgian Government, 2002). However, there are
data pointing possibly to socio-cultural rather than to socio-
economic factors since French-speaking communities in Swit-
zerland or Canada have a higher utilization of tranquilizer
medications compared to other communities living in the same
socio-economic environment [2]. In addition, several recent
studies have shown that the use of anxiolytic and hypnotic
drugs is much higher in France and Belgium than in neigh-
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boring countries [7,9,11]. For example, according to Pelis-
solo et al. [11], 25–30% of the French general population are
occasional or regular users of anxiolytic and hypnotic drugs
with between 5% and 7% chronic users, corresponding to
two to three times superior to most industrialized countries.
In the survey by Ohayon and Lader [9], France had the high-
est proportion of anxiolytic users (9.0%) followed by Italy
(5.8%); the rate was only 0.7% in Germany and 0.6% in the
UK. It should be noted that France and Belgium are charac-
terized by a more frequent recourse to most types of medica-
tions, reflecting probably differences in the attitude toward
illness and to differences in medical education. Future screen-
ing programs should collect information on socio-economic
factors such as marital status, level of education and employ-
ment in order to understand better differences in psychopa-
thology between Belgian regions. However, it can not totally
be excluded that differences in health-seeking behavior rather
than psychopathology per se differ between Belgian regions.
The proportion of diagnosed and not diagnosed patients who
presented with anxiety/depression as reason for consultation
in Dutch vs. French-speaking regions has been compared but
does not show any significant differences.
5.2. Impact
Regarding treatment in the screened population it is not
surprising to see that one in three positive patients use hyp-
notics, tranquilizers and/or antidepressants. The presence of
both diagnoses leads to higher frequencies of psychotropic
medication than in isolated disorders.
GADIS shows that approximately 10% of primary care
patients without depression or GAD take hypnotics and 14%
take tranquilizers. In patients with MD or GAD this rate
increases to 27% for hypnotics and 48% for tranquilizers.
Although the present study confirms the high use of benzo-
diazepines [12], it also shows that most of the patients with
MD do not receive the most appropriate treatment. Only 32%
of the patients that have depression or GAD receive an anti-
depressant at the time of the consultation. It is well estab-
lished that antidepressants are the most indicated pharmaco-
logical treatment for depression in primary care. More
recently, antidepressants have become the appropriate phar-
macological long-term treatment for chronic anxiety disor-
ders such as GAD [3]. It should be mentioned however that
non-pharmacological approaches, such as cognitive-
behavioral therapies have demonstrated interest in the treat-
ment of moderately severe forms of GAD and MD [4]. One
of the several explanations of a high use of benzodiazepines
in Belgium appears to be the prescription of BZD in a large
number of subjects with anxiety and/or depression. Indeed,
France and Belgium are characterized by extremely high ben-
zodiazepine use. Unfortunately, we did not collect in our study
precise data about the type of anxiolytic consumption (dura-
tion, occasional or chronic intake...).
The results from the patient rating Sheehan disability scale
show that the presence of GAD and/or MD are associated
with substantial impairment of social, professional and fam-
ily functioning. This confirms that GAD and MD are dis-
abling conditions [6,18].
The majority of positive patients have both GAD and
depression, confirming results from other studies. The patients
with GAD and depression are clearly more severely ill, with
higher scores on the Sheehan disability scale.
5.3. Limitations
Several limitations in the design of the study should be
acknowledged. First, the selection process of GP was not ran-
domized and could have included GP’s particularly inter-
ested in psychiatric patients. Therefore, the sample of patients
could eventually have been biased. It should be noted how-
ever that the size of the sample is rather large and that the
demographical characteristics of the patients correspond rea-
sonably well with those of the Belgian population. Second,
the GP’s were not trained in the use of the MINI. It should be
noted however that only the GAD and MD section of the MINI
were used and that the instrument appears rather simple. How-
ever, no inter-rater-reliability checks were obtained. Third,
the MINI is potentially over-inclusive concerning GAD diag-
noses because of the lack of a systematic and structured explo-
ration of differential diagnoses (affective disorders, anxiety
disorders, general medical conditions) in case of comorbid-
ity.
6. Conclusion
The lessons learned from GADIS are that GAD and MD
are frequent and debilitating illnesses that can easily be
detected, using the right instruments. Many GP told after-
wards (no formal assessment) that they have learned a lot
about the diagnosis of MD and GAD with the use of this
scale. Clearly, in primary care in Belgium and Luxemburg,
basic axis-I diagnosis for MD and GAD remains a problem
as well as the under prescription of antidepressants and the
over prescription of benzodiazepines.
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